Drug Profile
Luvadaxistat - Takeda
Alternative Names: NBI 1065844; TAK 831Latest Information Update: 17 Jan 2022
Price :
$50
*
At a glance
- Originator Takeda
- Class Antipsychotics; Fluorinated hydrocarbons; Ketones; Pyridazines; Small molecules
- Mechanism of Action D amino acid oxidase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Schizophrenia
- No development reported Ataxia
- Discontinued Friedreich's ataxia
Most Recent Events
- 07 Dec 2021 Takeda initiates a phase II trial in Schizophrenia (Adjunctive treatment) in USA (PO, Tablet) (NCT05182476)
- 28 Nov 2021 No recent reports of development identified for phase-I development in Ataxia(In volunteers) in Japan (PO, Tablet)
- 03 Aug 2021 Neurocrine Biosciences plans a phase II trial for Schizophrenia (Adjunctive treatment) in the second half of 2021